Company intelligence / Profile preview

LinusBio

New York, New York, United Stateslinusbio.com ↗

Ownership: Private
Development stage: Commercial

Overview

LinusBio has developed StrandDx, the first molecular autism spectrum disorder diagnostic biomarker, which received FDA Breakthrough designation. Their commercial product ClearStrand-ASD is now available as a rule-out diagnostic aid for autism that can identify biomarkers in children as young as one month old[1][3].

Therapeutic areas: GastroenterologyPsychiatryNeurology
Modalities: BiomarkersDiagnostic tests
Industry: Molecular Diagnostics

Drug pipeline

2 assets

ClearStrand-ASD

Commercial

Indications: Autism Spectrum Disorder

1 more asset in the full pipeline.

Request access →

Partnerships

Mount Sinai Health System

Beyond the preview

Go deeper on LinusBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LinusBio.

Explore the full profile